Citizens JMP upgraded Spruce Biosciences (SPRB) to Outperform from Market Perform with a $254 price target The firm cites the company’s acquisition of enzyme replacement therapy TA-ERT for Sanfilippo syndrome type B for the upgrade. TA-ERT has five-year data showing the ability to normalize heparin sulfate, the surrogate biomarker for accelerated approval, the analyst tells investors in a research note. Citizens models peak TAE-ERT sales of $170M, which it believes “could be conservative.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences price target raised to $160 from $10 at Leerink
- Spruce Biosciences Board Member Resigns
- Spruce Biosciences Stock Extends 2,900% Rally after FDA Breakthrough Therapy Designation Ignites Investor Frenzy
- Spruce Biosciences Secures $50 Million Investment Deal
- Biotech Alert: Searches spiking for these stocks today